Danielle Gershowitz

Cooley advised Aescape, the leader in artificial intelligence-powered recovery technology, on its acquisition of the exclusive rights to Tom Brady’s recovery and longevity protocols.

Cooley advised Riverwood Capital Advisors in connection with Riverwood Capital’s lead investment in AgendaPro’s $35 million Series B preferred stock financing. Riverwood Capital is a global growth equity firm that invests in high-growth technology companies across the Americas. AgendaPro is a Chile-based software as a service (SaaS) platform serving small- and medium-sized businesses in the wellness and beauty sectors across Latin America. Led by partners Danielle Gershowitz and Adam Dinow, the Cooley team provided strategic legal counsel to Riverwood Capital on the cross-border transaction.

Cooley advised Rillet, an artificial intelligence-native enterprise resource planning platform, on its $25 million Series A financing round.

Cooley advised HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome-targeting therapeutics, on its $65 million Series A financing round. The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company, ATHOS, +ND Capital, Alexandria Venture Investments, and LifeLink Ventures, with additional support from existing investors Apollo Health Ventures, Longview Ventures (an affiliate of Broadview Ventures), 4see ventures, BERNINA Bioinvest and Schroders Capital.

Lawyers Danielle Gershowitz, Josh Seidenfeld, Amanda Gonzalez Burton, Kristine Kevorkova and Thomas Heiser led the Cooley team advising HAYA Therapeutics.

Cooley represented Clay, a company that helps go-to-market teams up-level their data enrichment and automate personalized outreach, in its $40 million preemptive Series B expansion funding at a $1.25 billion valuation.